Interleukin-10 gene therapy reverses thioacetamide-induced liver fibrosis in mice
- 22 August 2005
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 336 (1) , 324-331
- https://doi.org/10.1016/j.bbrc.2005.08.085
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Adhesion molecules as a prognostic marker of liver cirrhosisScandinavian Journal of Gastroenterology, 2005
- Antifibrotic effects of a tissue inhibitor of metalloproteinase-1 antibody on established liver fibrosis in ratsHepatology, 2004
- Single injection of naked plasmid encoding α-melanocyte-stimulating hormone protects against thioacetamide-induced acute liver failure in miceBiochemical and Biophysical Research Communications, 2004
- Protective effect of MDL28170 against thioacetamide-induced acute liver failure in miceJournal of Biomedical Science, 2004
- Cirrhosis reversal: a duel between dogma and mythJournal of Hepatology, 2004
- Fibrosis progression in chronic hepatitis C virus infectionGut, 2004
- Non‐viral human IL‐10 gene expression reduces acute rejection in heterotopic auxiliary liver transplantation in ratsMicrosurgery, 2003
- JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosisGastroenterology, 2003
- Liver fibrosis – from bench to bedsideJournal of Hepatology, 2003
- Interleukin-10 modulates type I collagen and matrix metalloprotease gene expression in cultured human skin fibroblasts.Journal of Clinical Investigation, 1994